L‐asparaginase doses number as a prognostic factor in childhood acute lymphoblastic leukemia: A survival analysis study
Open Access
- 24 August 2021
- journal article
- research article
- Published by Wiley in Cancer Reports
- Vol. 5 (8) , e1533
Abstract
Background: The survival of children with acute lymphoblastic leukemia (ALL) has improved due to changes in the treatment and the disease diagnosis. A significant advance was the incorporation of asparaginase. However, hypersensitivity reactions are a common cause of early discontinuation of this drug.Aim: The proposed study aims to evaluate early interruptions and the influence of the number of asparaginase doses effectively administered on the prognosis of patients with ALL.Methods and Results: An observational cohort study was carried out, with retrospective data collection, in medical records. The prognostic variables indicated in the protocol applied were used, and the principal outcomes were 5 years event‐free survival (EFS) and 5 years of overall survival (OS) probability. Statistical analyzes were performed using SPPS 20.0 and R. In Cox's proportional hazards model for EFS and OS, variables of prognostic importance (n = 126 children) were: high‐risk group (HGR), by the protocol classification, and less than 10 doses of asparaginase. The increased risk of events and death in HGR, who did less than 10 doses, was 3.6 and 7 times, respectively. The study did not show statistical significance for the number of asparaginase doses in patients who were not at high risk.Conclusions: We demonstrated that the early interruption of asparaginase treatment could negatively impact the prognosis of patients with ALL, especially HGR, reinforcing the need for careful diagnosis of reactions and the availability of alternative types of asparaginase.Keywords
This publication has 19 references indexed in Scilit:
- Is Erwinase Necessary for all Children With ALL and Allergic Reactions toE. coliAsparaginase?Pediatric Blood & Cancer, 2016
- Childhood Acute Lymphoblastic Leukemia: Progress Through CollaborationJournal of Clinical Oncology, 2015
- Allergic reactions and antiasparaginase antibodies in children with high‐risk acute lymphoblastic leukemia: A children's oncology group reportCancer, 2015
- How to manage asparaginase hypersensitivity in acute lymphoblastic leukemiaFuture Oncology, 2014
- Intensive Chemotherapy for Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Intercontinental Trial ALL IC-BFM 2002Journal of Clinical Oncology, 2014
- Managing Hypersensitivity to Asparaginase in Pediatrics, Adolescents, and Young AdultsJournal of Pediatric Oncology Nursing, 2013
- Tolerability and Efficacy of L-Asparaginase Therapy in Pediatric Patients With Acute Lymphoblastic LeukemiaJournal of Pediatric Hematology/Oncology, 2010
- L‐asparaginase treatment in acute lymphoblastic leukemiaCancer, 2010
- Pharmacokinetic/Pharmacodynamic Relationships of Asparaginase FormulationsClinical Pharmacokinetics, 2005
- Survival Analysis Part II: Multivariate data analysis – an introduction to concepts and methodsBritish Journal of Cancer, 2003